Research analyst, medium-term horizon, biotech, small-cap

Neuralstem NSI-189 Abstract Teases At Potential Greatness

On May 23, 2014, Neuralstem, Inc. (NYSEMKT:CUR) announced that much anticipated data from the Phase 1b study of small-molecule NSI-189 will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Hollywood, Florida on June 17th at 4:15 EDT. We have been waiting for this data since the Phase 1b program first began in December 2011. The trial completed in the fourth quarter of 2013, but Neuralstem has been very quiet about the results from this study for a number of reasons. The principal investigator is Maurizio Fava, Director of the Clinical Research Program and Executive Vice Chair, Department of Psychiatry at the Massachusetts General Hospital in Boston, MA. Dr. Fava is also Professor of

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details